The DOI matches its Crossref record.
Real‐world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45‐year period
Open accessAbstract
Summary: The prognostic landscape of multiple myeloma (MM) has evolved significantly over the last few decades. There are, however, few data measuring such improvement in real‐world patients. This study aimed to investigate trends in survival improvement over 45 years, and the associated clinical factors, in an unselected population of patients with MM. Between 1970 and 2015, 1 161 MM patients were included. Patients were classified into three calendar periods (1970–1984, 1985–1999, and 2000–2015), according to the treatment received; polychemotherapy, autologous stem cell transplantation, and novel drugs respectively. We analysed relative survival (RS) to accurately evaluate MM‐related death rates after excluding the mortality expected in the general population. RS at five years increased from 27% in 1970–1984 to 38% and 56% in the next two calendar periods respectively. The improvement to survival was greater in the younger population, but it was also observed in elderly patients and those with poor performance status and more advanced disease. Although myeloma is still a non‐curable disease, encouraging results have been observed in the last decades. Progress is expected to continue with the use of new generations of anti‐myeloma drugs, and will, hopefully, be documented in real‐world patients by the appropriate population‐based studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Most patients with multiple myeloma have a relapse after standard treatment, and outcomes worsen with each subsequent line of therapy.
“outcomes worsen with each subsequent line of therapy. 3-5”
From Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. (2023) · cites this paper as [2]
The citation is attached to the claim that outcomes worsen with each subsequent line of therapy. The Discussion says few patients reached later lines, and Specific outcomes compares the number of lines received across calendar periods, but neither reports outcomes by successive treatment line. The Introduction supports the separate point that most patients ultimately relapse, not the cited sentence's claim. (LLM, conf=0.75)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 55
- 10.1002/ijc.22718 · DOI
- 10.1002/cncr.20652 · DOI
- 10.4065/mcp.2009.0426 · DOI
- 10.3324/haematol.2017.178103 · DOI
- 10.1016/j.annonc.2020.11.014 · DOI · Paper page
- 10.3390/hemato2010001 · DOI
- 10.3389/fonc.2020.01243 · DOI
- Bruno B, 2021, European myeloma network perspective on CAR T‐Cell therapies for multiple myeloma, Haematologica, 106, 2054, 10.3324/haematol.2020.276402 · DOI
- 10.1200/JCO.2009.25.4177 · DOI
- 10.1016/j.bbmt.2015.06.004 · DOI
- 10.1038/s41408-018-0141-0 · DOI
- 10.1111/ejh.13083 · DOI
- 10.1634/theoncologist.2011-0229 · DOI
- 10.1016/j.ejca.2015.08.003 · DOI
- 10.1111/bjh.13537 · DOI
- 10.1038/leu.2014.23 · DOI
- 10.1182/blood-2007-08-104984 · DOI
- 10.3324/haematol.13782 · DOI
- 10.1182/bloodadvances.2016002493 · DOI
- 10.1200/JCO.2006.09.0100 · DOI
- 10.3109/10428194.2014.897700 · DOI
- 10.1007/s12185-011-0971-z · DOI
- 10.1016/j.canep.2018.01.015 · DOI
- 10.1111/bjh.16674 · DOI
- 10.1038/s41408-020-0323-4 · DOI
- Chang‐Chan D‐Y‐L, 2021, Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty‐three‐year population‐based study, Clin Transl Oncol off Publ Fed Span Oncol Soc Natl Cancer Inst Mex, 23, 1429
- 10.1016/j.canep.2015.08.002 · DOI
- 10.1046/j.1365-2141.2003.04355.x · DOI
- 10.1111/j.1365-2141.1989.tb04314.x · DOI
- 10.1097/00000421-198212000-00014 · DOI
- 10.1046/j.1365-2141.1998.00930.x · DOI
- 10.1038/sj.leu.2404284 · DOI · Paper page
- 10.1182/blood-2010-10-299487 · DOI · Paper page
- 10.1111/j.1365-2141.1994.tb04986.x · DOI
- 10.1177/1536867X1501500112 · DOI
- 10.1002/(SICI)1097-0142(19961101)78:9<2004::AID-CNCR23>3.0.CO;2-# · DOI
- 10.1038/sj.bmt.1705727 · DOI
- 10.1200/JCO.2008.16.1000 · DOI
- 10.1038/s41408-020-00353-8 · DOI
- 10.1016/S1470-2045(14)70282-7 · DOI
- 10.1200/JCO.2017.76.6402 · DOI
- 10.1111/ejh.13374 · DOI
- 10.3109/10428194.2015.1041386 · DOI
- 10.1111/j.1600-0609.2012.01784.x · DOI
- 10.1038/leu.2015.33 · DOI
- 10.1186/s12885-016-2645-y · DOI
- 10.1200/JCO.2005.03.2086 · DOI
- 10.1038/leu.2013.313 · DOI
- 10.1111/bjh.14213 · DOI · Paper page
- 10.1111/j.1365-2141.2011.08905.x · DOI
- 10.1016/j.bbmt.2012.09.023 · DOI
- 10.1016/j.bbmt.2014.12.028 · DOI
- 10.1016/S1470-2045(13)70609-0 · DOI
- 10.1111/bjh.15426 · DOI
- 10.1093/annonc/mdw606 · DOI
Cited by
Sorted by citations
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303379 · Cited by 827
Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma
Puertas, B., González‐Calle, V., Sobejano, E., Escalante, F., Queizán, J. A., Bárez, A., Labrador, J., Alonso, J. M., de Coca, A. G., Cantalapiedra, A. M. T., et al. (2023) · Cancers · doi:10.3390/cancers15051558 · Cited by 88
Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., Bahlis, N. J., et al. (2024) · Blood · doi:10.1182/blood.2024024582 · Cited by 79
Mateos, M., Weisel, K., Stefano, V. D., Goldschmidt, H., Delforge, M., Mohty, M., Dytfeld, D., Angelucci, E., Vincent, L., Perrot, A., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02404-6 · Cited by 46
“With recent advances in multiple myeloma (MM) treatment, patients with MM are living longer [1 – 3].”
Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades
Pasvolsky, O., Marcoux, C., Dai, J., Milton, D. R., Tanner, M. R., Syed, N., Bashir, Q., Srour, S. A., Saini, N. Y., Lin, P. Y., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.06.001 · Cited by 10
Long-Term Responders After Autologous Stem Cell Transplantation in Multiple Myeloma
Oliver‐Caldés, A., Soler-Perromat, J. C., Lozano, E., Moreno, D. F., Bataller, Á., Mozas, P., Garrote, M., Setoaín, X., Aróstegui, J. I., Yagüe, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.936993 · Cited by 10
“Despite these therapeutic improvements, MM remains virtually incurable, with a progressively shorter duration of response to each consecutive line of treatment (3, 4).”
BackgroundSelf-citationOrtega-Vida, E., Rosado-Rodriguez, A., Fe, R., Verdugo, V., Gavira, R., & Garzón, S. (2025) · Cancers · doi:10.3390/cancers17050793 · Cited by 9
“In these specialized settings, recent studies from Spanish centers have reported OS rates ranging from 86.7 to 103.6 months [31–33].”
InfluentialBattram, A. M., Mañé-Pujol, J., Moreno, D. F., Oliver‐Caldés, A., Carpio, J., Cardús, O., Rodríguez‐Lobato, L. G., Urbano-Ispizúa, Á., & de Larrea, C. F. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013209 · Cited by 10
Self-citationMikulski, D., Nowicki, M., Dróźdż, I., Misiewicz, M., Kościelny, K., Okoński, K., Krawiec, K. M., Perdas, E., Wierzbowska, A., & Fendler, W. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1250355 · Cited by 8
“In recent years, a significant breakthrough was made in patient outcomes due to novel medications such as proteasome inhibitors (PI), immunomodulatory drugs (IMiDs), and monoclonal antibodies (2, 3).”
Dores, G., Vo, J., Schonfeld, S., Shing, J. Z., Taparra, K., Morton, L. M., Curtis, R. E., & Linet, M. (2025) · British Journal of Haematology · doi:10.1111/bjh.20192 · Cited by 5
“44 We assessed patient survival according to year of diagnosis within each of four 5-year calendar periods: 2000–2004 (introduction of the first proteosome inhibitor for relapsed/refractory MM), 2005–2009 (introduction of immunomodulatory drugs for newly diagnosed or relapsed/refractory MM),…”
Rodríguez-Lobato, L., Tovar, N., de Daniel, A., de Larrea, C. F., Cibeira, M., Jiménez-Segura, R., Moreno, D. F., Oliver-Cáldes, A., Bladé, J., & Rosiñol, L. (2023) · Cancers · doi:10.3390/cancers15215261 · Cited by 3
Self-citationTouzeau, C., Lipe, B., Khan, A., Dhakal, B., Nair, S., He, J.-M., Mendes, J., Lee, S. P., Lonardi, C., Slaughter, A. R., et al. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03308-2 · Cited by 2
Ivakhnenko, O., Ryazhenov, V., & Falaleeva, N. (2024) · FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology · doi:10.17749/2070-4909/farmakoekonomika.2024.237 · Cited by 1
Minimal residual disease in multiple myeloma: the movement towards response-adapted therapy
Lim, K. J. C., Pertile, H., & Spencer, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1932648
Cardús, O., Mañé-Pujol, J., de Daniel, A., Moreno, D. F., Gremen, T., Battram, A. M., Vaqué-Salsench, S., Pérez-Amill, L., Llobregat, H., Mármol, J. C., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011864
Self-citationPeng, L., Shan, T., Zhou, X., Feng, Z., Qiang, W., Lü, J., He, H., & Du, J. (2025) · OncoTargets and Therapy · doi:10.2147/ott.s516486
Metadata
- Authors
- Rodríguez‐Lobato, L. G., Pereira, A., Fernández de Larrea, C., Cibeira, M. T., Tovar, N., Jiménez‐Segura, R., Moreno, D. F., Oliver‐Caldés, A., Rosiñol, L., & Bladé, J.
- Affiliations
- Hospital Clínic de Barcelona (ES)
- Amyloidosis and Multiple Myeloma Unit Department of Hematology Hospital Clínic of Barcelona Barcelona Spain
- Corresponding author
- Rodríguez‐Lobato, Luis Gerardo
- ORCID
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2021-10-07
- Volume
- 196
- Issue
- 3
- Pages
- 649-659
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W3202591757
- Cited by
- 19
- References
- 0
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 5 · 2023: 5 · 2022: 1
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- British Journal of Haematology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- H2020 Marie Skłodowska-Curie Actions (754550)
- Instituto de Salud Carlos III (ICI19/00025, PI19/00669)
- European Regional Development Fund (2017SGR00792)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Keywords
- multiple myeloma, survival trends, relative survival, prognostic factors, autologous stem cell transplantation, combination chemotherapy, age at diagnosis, performance status, disease stage, long-term outcomes
- MeSH terms
- Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Mortality, Multiple Myeloma, Neoplasm Staging, Disease Management, History, 20th Century, History, 21st Century, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
